It is looking likely that a third PARP inhibitor will soon be available in Europe to patients with ovarian cancer with Clovis Oncology Inc.'s announcement that it expects a recommendation for approval for Rubraca (rucaparib) from the EU's regulators at the end of next month.
The company says that following a meeting with the European Medicines Agency's Scientific Advisory Group Oncology last week and an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?